CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTMX
Previous Symbol
CUSIPN/A
Phone650-515-3185
Debt
Debt-to-Equity RatioN/A
Current Ratio5.48
Quick Ratio5.48
Price-To-Earnings
Trailing P/E Ratio-12.47
Forward P/E Ratio-8.08
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.62 million
Price / Sales9.09
Cash FlowN/A
Price / CashN/A
Book Value$3.50 per share
Price / Book4.13
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-43,090,000.00
Net Margins-68.90%
Return on Equity-65.03%
Return on Assets-12.67%
Miscellaneous
Employees93
Outstanding Shares45,010,000
Market Cap$619.75 million
OptionableOptionable
CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions
What is CytomX Therapeutics' stock symbol?
CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."
How were CytomX Therapeutics' earnings last quarter?
CytomX Therapeutics Inc (NASDAQ:CTMX) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.11. The biotechnology company earned $12.51 million during the quarter, compared to analyst estimates of $16.42 million. CytomX Therapeutics had a negative net margin of 68.90% and a negative return on equity of 65.03%. View CytomX Therapeutics' Earnings History.
When is CytomX Therapeutics' next earnings date?
What price target have analysts set for CTMX?
9 analysts have issued 12-month price objectives for CytomX Therapeutics' shares. Their forecasts range from $21.00 to $40.00. On average, they expect CytomX Therapeutics' share price to reach $35.8571 in the next year. This suggests a possible upside of 148.0% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics.
What is the consensus analysts' recommendation for CytomX Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics.
What are Wall Street analysts saying about CytomX Therapeutics stock?
Here are some recent quotes from research analysts about CytomX Therapeutics stock:
- 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (11/9/2018)
- 2. Cann analysts commented, "Loss per share was $0.53, compared to our estimated EPS of $0.00. This was primarily the result of higher than expected operating expenses, which exceeded our estimate by 26.7%. R&D expense of $27.5 million was higher than our estimated $19.1 million. In addition, collaboration revenue was lower than expected due to a change in collaboration revenue recognition. A detailed, and promising, pipeline and regulatory update was provided and is included in this report." (11/6/2018)
- 3. HC Wainwright analysts commented, "We have valued CytomX Therapeutics based on a discounted cash flow (DCF) assessment that is driven by a combination of CX-072 future sales and BMS-986249 future royalties on net sales." (9/13/2018)
Has CytomX Therapeutics been receiving favorable news coverage?
News headlines about CTMX stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CytomX Therapeutics earned a news impact score of 3.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the immediate future.
Who are some of CytomX Therapeutics' key competitors?
Some companies that are related to CytomX Therapeutics include Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Allakos (ALLK), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), ACADIA Pharmaceuticals (ACAD), Myokardia (MYOK), Heron Therapeutics (HRTX), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Pacira Pharmaceuticals (PCRX), Amicus Therapeutics (FOLD) and Endocyte (ECYT).
Who are CytomX Therapeutics' key executives?
CytomX Therapeutics' management team includes the folowing people:
- Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)
- Mr. Debanjan Ray, CFO & Head of Corp. Devel. (Age 40)
- Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 57)
- Dr. W. Michael Kavanaugh, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)
- Ms. Danielle Olander, Sr. VP of Talent & Admin. Operations
Who are CytomX Therapeutics' major shareholders?
CytomX Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (8.60%), Perceptive Advisors LLC (5.91%), Renaissance Technologies LLC (3.38%), Point72 Asset Management L.P. (2.95%) and Victory Capital Management Inc. (1.98%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Rachel Humphrey, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.
Which major investors are selling CytomX Therapeutics stock?
CTMX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Russell Investments Group Ltd., TIAA CREF Investment Management LLC, First Trust Advisors LP, Panagora Asset Management Inc., GSA Capital Partners LLP, Virtus ETF Advisers LLC and AQR Capital Management LLC. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Rachel Humphrey and Sean A Mccarthy. View Insider Buying and Selling for CytomX Therapeutics.
Which major investors are buying CytomX Therapeutics stock?
CTMX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Victory Capital Management Inc., Perceptive Advisors LLC, BlackRock Inc., Candriam Luxembourg S.C.A., Sphera Funds Management LTD. and Renaissance Technologies LLC. View Insider Buying and Selling for CytomX Therapeutics.
How do I buy shares of CytomX Therapeutics?
Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytomX Therapeutics' stock price today?
One share of CTMX stock can currently be purchased for approximately $14.46.
How big of a company is CytomX Therapeutics?
CytomX Therapeutics has a market capitalization of $619.75 million and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.
What is CytomX Therapeutics' official website?
How can I contact CytomX Therapeutics?
CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]
MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
